These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 8635863)

  • 1. Pharmacokinetics, biodistribution and biological effects of intravenously administered bispecific monoclonal antibody OC/TR F(ab')2 in ovarian carcinoma patients.
    Tibben JG; Boerman OC; Massuger LF; Schijf CP; Claessens RA; Corstens FH
    Int J Cancer; 1996 May; 66(4):477-83. PubMed ID: 8635863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumour targeting of the anti-ovarian carcinoma x anti-CD3/TCR bispesific monoclonal antibody OC/TR and its parental MOv18 antibody in experimental ovarian cancer.
    Boerman OC; Tibben JG; Massuger LF; Claessens RA; Corstens FH
    Anticancer Res; 1995; 15(5B):2169-74. PubMed ID: 8572619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric bispecific OC/TR monoclonal antibody mediates lysis of tumor cells expressing the folate-binding protein (MOv18) and displays decreased immunogenicity in patients.
    Luiten RM; Warnaar SO; Sanborn D; Lamers CH; Bolhuis RL; Litvinov SV; Zurawski VR; Coney LR
    J Immunother; 1997 Nov; 20(6):496-504. PubMed ID: 9409456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Purification of bispecific F(ab')2 from murine trinoma OC/TR with specificity for CD3 and ovarian cancer.
    Warnaar SO; De Paus V; Lardenoije R; Machielse BN; De Graaf J; Bregonje M; Van Haarlem H
    Hybridoma; 1994 Dec; 13(6):519-26. PubMed ID: 7737675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and in vivo stability and anti-tumour efficacy of an anti-EGFR/anti-CD3 F(ab')2 bispecific monoclonal antibody.
    Negri DR; Tosi E; Valota O; Ferrini S; Cambiaggi A; Sforzini S; Silvani A; Ruffini PA; Colnaghi MI; Canevari S
    Br J Cancer; 1995 Oct; 72(4):928-33. PubMed ID: 7547242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2.
    Kroesen BJ; Buter J; Sleijfer DT; Janssen RA; van der Graaf WT; The TH; de Leij L; Mulder NH
    Br J Cancer; 1994 Oct; 70(4):652-61. PubMed ID: 7917912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bispecific monoclonal antibodies for intravenous treatment of carcinoma patients: immunobiologic aspects.
    Kroesen BJ; Janssen RA; Buter J; Nieken J; Sleijfer DT; Mulder NH; De Leij L
    J Hematother; 1995 Oct; 4(5):409-14. PubMed ID: 8581377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy in a human ovarian cancer xenograft model with two bispecific monoclonal antibodies: OV-TL 3/CD3 and OC/TR.
    van Ravenswaay Claasen HH; Eggermont AM; Nooyen YA; Warnaar SO; Fieuren GJ
    Gynecol Oncol; 1994 Feb; 52(2):199-206. PubMed ID: 8314139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD3-CD28 costimulation as a means to avoiding T cell preactivation in bispecific monoclonal antibody-based treatment of ovarian carcinoma.
    Mazzoni A; Mezzanzanica D; Jung G; Wolf H; Colnaghi MI; Canevari S
    Cancer Res; 1996 Dec; 56(23):5443-9. PubMed ID: 8968099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of bispecific monoclonal antibody (bsAb)-targeted cytolysis by human anti-mouse antibodies in ovarian carcinoma patients treated with bsAb-targeted activated T-lymphocytes.
    Lamers CH; Gratama JW; Warnaar SO; Stoter G; Bolhuis RL
    Int J Cancer; 1995 Feb; 60(4):450-7. PubMed ID: 7829257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody.
    Canevari S; Stoter G; Arienti F; Bolis G; Colnaghi MI; Di Re EM; Eggermont AM; Goey SH; Gratama JW; Lamers CH
    J Natl Cancer Inst; 1995 Oct; 87(19):1463-9. PubMed ID: 7674333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD3 directed bispecific antibodies induce increased lymphocyte-endothelial cell interactions in vitro.
    Molema G; Tervaert JW; Kroesen BJ; Helfrich W; Meijer DK; de Leij LF
    Br J Cancer; 2000 Jan; 82(2):472-9. PubMed ID: 10646907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytokine release in an ovarian carcinoma patient following intravenous administration of bispecific antibody OC/TR F(ab')2.
    Tibben JG; Boerman OC; Claessens RA; Corstens FH; van Deuren M; de Mulder PH; van der Meer JW; Keijser KG; Massuger LF
    J Natl Cancer Inst; 1993 Jun; 85(12):1003-4. PubMed ID: 8496973
    [No Abstract]   [Full Text] [Related]  

  • 14. Biodistribution of indium-111-labeled OC 125 monoclonal antibody intraperitoneally injected into patients operated on for ovarian carcinomas.
    Chatal JF; Saccavini JC; Gestin JF; Thédrez P; Curtet C; Kremer M; Guerreau D; Nolibé D; Fumoleau P; Guillard Y
    Cancer Res; 1989 Jun; 49(11):3087-94. PubMed ID: 2720667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Local but no systemic immunomodulation by intraperitoneal treatment of advanced ovarian cancer with autologous T lymphocytes re-targeted by a bi-specific monoclonal antibody.
    Lamers CH; Bolhuis RL; Warnaar SO; Stoter G; Gratama JW
    Int J Cancer; 1997 Oct; 73(2):211-9. PubMed ID: 9335445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Level of anti-mouse-antibody response induced by bi-specific monoclonal antibody OC/TR in ovarian-carcinoma patients is associated with longer survival.
    Miotti S; Negri DR; Valota O; Calabrese M; Bolhuis RL; Gratama JW; Colnaghi MI; Canevari S
    Int J Cancer; 1999 Feb; 84(1):62-8. PubMed ID: 9988234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Localization of monoclonal antibody G250 and bispecific monoclonal antibody CD3/G250 in human renal-cell carcinoma xenografts: relative effects of size and affinity.
    van Dijk J; Zegveld ST; Fleuren GJ; Warnaar SO
    Int J Cancer; 1991 Jul; 48(5):738-43. PubMed ID: 1830033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. OKT3 F(ab')2 fragments--retention of the immunosuppressive properties of whole antibody with marked reduction in T cell activation and lymphokine release.
    Woodle ES; Thistlethwaite JR; Ghobrial IA; Jolliffe LK; Stuart FP; Bluestone JA
    Transplantation; 1991 Aug; 52(2):354-60. PubMed ID: 1908148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting of human breast cancer by a bispecific antibody directed against two tumour-associated antigens: ErbB-2 and carcinoembryonic antigen.
    Dorvillius M; Garambois V; Pourquier D; Gutowski M; Rouanet P; Mani JC; Pugnière M; Hynes NE; Pèlegrin A
    Tumour Biol; 2002; 23(6):337-47. PubMed ID: 12677091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regional and systemic distribution of anti-tumor x anti-CD3 heteroaggregate antibodies and cultured human peripheral blood lymphocytes in a human colon cancer xenograft.
    Nelson H; Ramsey PS; Kerr LA; McKean DJ; Donohue JH
    J Immunol; 1990 Nov; 145(10):3507-15. PubMed ID: 1700013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.